Skip to main content
Log in

Association of SGLT2is with respiratory and skin diseases

  • Correspondence
  • Published:
Endocrine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. L. Li, Y.H. Dong, Y. Bai, Z.Y. Tang, Y.M. Deng, Z. Wu et al. Association of sglt2is with cardiovascular and reproductive diseases: a meta-analysis based on 14 large-scale randomized trials. Endocrine. 2023. https://doi.org/10.1007/s12020-023-03618-x.

  2. M. Qiu, L.L. Ding, Z.L. Zhan, S.Y. Liu, Use of sglt2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of sglt2 inhibitors. Endocrine 73(1), 31–36 (2021). https://doi.org/10.1007/s12020-021-02644-x

    Article  CAS  PubMed  Google Scholar 

  3. A. Kang, B. Smyth, B.L. Neuen, H. Heerspink, G.L. Di Tanna H. Zhang et al. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: a pooled post hoc analysis from the canvas program and credence randomized double-blind trials. Diabetes Obes. Metab. 25(8), 2151–2162 (2023). https://doi.org/10.1111/dom.15091

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chao Liu.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xiao, Y., Peng, S. & Liu, C. Association of SGLT2is with respiratory and skin diseases. Endocrine (2024). https://doi.org/10.1007/s12020-024-03739-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12020-024-03739-x

Keywords

Navigation